2、永赢基金的投研体系是以一群核心能力互补的专业人士，共同构建的具有完备性、实战性，同时不断迭代的投资体 系构成的"1"。同叠加在尊重投资客观规律基础上的，以追求高效率的投资表达为目标，进行设计和最优人员匹配的不 同形态产品构成的"N"。打造而成的"1+N"投资体系。 3、大国崛起的竞争力可以从"货币地位、国防实力、科技创新"三大维度得到论证。当年美国资本市场的地位是建立 在"强势美元，国防安全，和持续的科技创新推动经济高质量发展" 这三大基础之上的，中国也正在这三个维度取得突 破。 4、逐鹿者不顾兔，展望下半年，聚焦硬科技（AI/军工）及新质生产力主线，"锚定主导科技"，才能让我们的关注方 向更聚焦，才能起到事半功倍的效果。 过去两年，永赢基金作为国内绩优基金辈出的机构，经常出现在市场和投资者的面前。 2025年7月9日，以 "赢"接硬核科技时代为主题的永赢基金2025年中策略会隆重召开！ 这场只讲纯干货、解码硬科技的 策略盛会，不仅公开了多位基金经理最新的市场观点，也透露了其压箱底的权益投资体系和产品策略。 永赢基金的权益投资体系是怎样的？他们近两年做对了什么？还想继续做什么？他们对市场机会的看法究竟如何 ...

Core Insights - The pharmaceutical sector has experienced a slowdown in momentum after a strong rally earlier in the year, with the number of "doubling funds" significantly decreasing [1][2] - As of November 28, only two pharmaceutical-themed funds maintained over 100% returns, indicating a retreat from previous high performance [2] - The industry is currently in a transitional phase characterized by increased market speculation, despite a solid long-term growth outlook supported by policy reinforcement and improved cash flow [1][3] Fund Performance - As of November 28, the only two funds with over 100% returns are Zhongyin Hong Kong Stock Connect Pharmaceutical A (up 107.69%) and Chuangjin Hexin Global Pharmaceutical Biotechnology A (up 100.32%) [2] - The average return of pharmaceutical-themed funds has retreated approximately 10% from their peak in September [2] - Major pharmaceutical ETFs have seen a decline in scale over the past three months, reflecting a shift from aggressive buying to a more cautious stance [2] Policy Environment - The policy landscape is expected to remain favorable for the pharmaceutical industry, with significant measures announced to support high-quality development [3][4] - Key policies include a comprehensive support framework for innovative drugs, scientific regulation, and standardized development of traditional Chinese medicine [3] - The upcoming negotiations for the national basic medical insurance directory are anticipated to enhance funding sources for the healthcare industry [3][4] Valuation and Market Dynamics - The pharmaceutical sector has been ranked low in relative performance over the past four years, indicating a potential for upward valuation adjustments [5][6] - The market is transitioning from short-term trading strategies to a focus on valuation recovery, with signs of performance improvement following the third-quarter earnings reports [5][6] - Positive catalysts are expected in the fourth quarter, including accelerated business development and improved cash flow for leading companies [6]

Core Viewpoint - The pharmaceutical sector has experienced a slowdown in its upward momentum after a strong rally earlier in the year, with the number of "doubling funds" significantly decreasing [1][2]. Group 1: Market Performance - As of November 28, only two pharmaceutical-themed funds, Zhongyin Hong Kong Stock Connect Pharmaceutical A and Chuangjin Hexin Global Pharmaceutical Biotechnology A, maintained doubling returns, with gains of 107.69% and 100.32% respectively, indicating a notable contraction compared to previous performance [3]. - In the third quarter, multiple pharmaceutical funds saw significant net value increases, but by the end of November, the average return for pharmaceutical-themed funds had retreated approximately 10% from their September peak [3]. - Major pharmaceutical ETFs, including the CSI 300 Pharmaceutical and Health Index and the CSI All Share Pharmaceutical and Health Index, have also seen a decline in scale over the past three months, reflecting a shift in investor sentiment from aggressive buying to cautious observation [3]. Group 2: Policy Environment - The policy landscape is viewed as a stabilizing factor for the pharmaceutical sector, with institutions focusing on policy and industry dynamics to gauge future trends [4]. - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, providing comprehensive support across research, access, clinical application, and payment mechanisms [5]. - Regulatory improvements, such as the implementation of ICH guidelines and encouragement of real-world studies for drug safety assessments, are expected to enhance the efficiency and scientific rigor of drug approvals [5]. Group 3: Valuation and Investment Outlook - The pharmaceutical industry has ranked relatively low in terms of valuation over the past four years, suggesting significant potential for upward movement as valuations have been sufficiently digested [6]. - Following a period of correction, the relative value of the pharmaceutical sector is becoming more apparent, with a shift in investment logic from short-term trading to valuation recovery [6]. - Positive signs of recovery are emerging in the pharmaceutical sector's fundamentals, with improved performance reported in the third quarter and expectations for accelerated business development in the fourth quarter [6]. - The Federal Reserve's interest rate cuts are anticipated to facilitate a recovery in pharmaceutical financing, alongside improvements in the domestic capital market, which will likely enhance new drug research and development spending [7].

Group 1: Market Performance - The A-share market has shown strong performance this year, with the Shanghai Composite Index rising by 19.25%, the Shenzhen Component Index by 29.52%, and the ChiNext Index by 51.03% as of October 27 [1][2] - The Hang Seng Index and the Hang Seng Technology Index have also increased by 31.77% and 38.11% respectively [1] - Over 30 equity funds have doubled their returns this year, with some funds achieving over 100% returns [2] Group 2: Fund Performance and Strategy - The average return for over 1,000 ordinary stock funds is 31.21%, with a median return of 29.01% [2] - Notable funds like Yongying Technology Select A have reported a return of 206.10% year-to-date, while others like China Europe Digital Economy A have achieved 138.72% [3][4] - Fund managers are advising investors to diversify their investments to mitigate risks associated with high valuations in the AI sector [4] Group 3: Sector Insights - The technology sector, particularly companies involved in optical packaging, has been a significant contributor to fund performance [3] - The CPO index has seen a rise of over 100% this year, indicating strong growth in this segment [3] - The healthcare sector has shown mixed results, with some funds underperforming despite a previous uptrend in the medical index [5] Group 4: Fund Manager Insights - Fund managers are increasingly cautious about the high valuations in the AI sector, suggesting that some stocks may be overvalued based on optimistic growth expectations [4] - There is a call for a balanced approach in asset allocation, emphasizing the importance of not concentrating investments in a single sector [4][5] - The healthcare sector is undergoing a rationalization phase, with funds adjusting their portfolios to include a mix of innovative and generic drugs [5] Group 5: Research and Analysis Trends - Public funds are intensifying their research efforts during the earnings report season, with a significant increase in the number of companies being surveyed [6][7] - The pharmaceutical and biotechnology sectors are receiving the most attention from public fund managers, indicating a focus on validating company performance and growth potential [6][7]

Group 1 - The core point of the article highlights a significant decline in the number of "doubling funds" in the A-share market, with over half disappearing in less than ten trading days due to high volatility and corrections in leading sectors like innovative pharmaceuticals and technology [1][2] - As of October 21, only 25 funds with a cumulative increase of over 100% remained, a sharp drop from 53 at the end of September, indicating a substantial contraction in the "doubling fund" category [2][3] - The innovative pharmaceutical index and the Hong Kong Stock Connect innovative pharmaceutical index have seen declines of 9.17% and 11.59% respectively since October, with both indices retreating over 13% from their yearly highs [2][3] Group 2 - Despite the recent corrections, funds focused on technology and pharmaceuticals still dominate, with top performers like Yongying Technology Smart A achieving a 194.96% annual return [3][4] - The number of "doubling funds" fluctuated dramatically, reaching a low of just 8 on October 14, but rebounded as the technology sector showed signs of recovery [3][4] - Recent inflows into pharmaceutical ETFs indicate continued investor interest, with significant net inflows recorded for several funds since the beginning of October [3][5] Group 3 - Analysts suggest that the recent market adjustments may provide better investment opportunities, as the corrections are seen as a release of risk rather than a long-term trend [5][6] - The shift in market style from growth to value is attributed to factors such as U.S.-China trade tensions and profit-taking by investors after substantial gains in technology stocks [6][7] - The long-term outlook for innovative pharmaceuticals remains positive, with expectations of continued growth driven by successful business development and clinical advancements [7][8]

Core Viewpoint - The A-share market has shown a clear "track market" characteristic this year, with significant performance in sectors like AI and innovative pharmaceuticals, while traditional sectors like consumption and banking are struggling [1][2]. Group 1: Market Performance - As of October 10, 2023, 53 funds have doubled their performance year-to-date, with 43 of these being actively managed equity products, highlighting the advantage of active management in a structural market [2][3]. - The technology and pharmaceutical sectors have emerged as the biggest winners, with top-performing funds like Yongying Technology Smart A achieving a return of 187.86% [2]. - The overall performance of the A-share market has been mixed, with over 96% of equity products showing positive returns, but 20 funds still experiencing declines of over 10% [3]. Group 2: Impact of External Factors - The recent escalation of the US-China tariff conflict has introduced new uncertainties to the market, with the A-share indices experiencing slight declines on October 13, 2023 [1][5]. - Analysts believe the current market reaction to the tariff threat is different from the sharp declines seen in April, as the market has become somewhat immune to such threats due to previous experiences [5][6]. - The consensus among analysts is that while short-term market fluctuations may occur, the long-term focus on technology and growth sectors remains unchanged [7]. Group 3: Investment Strategies - In light of the current market conditions, it is suggested that investors focus on funds with mature strategies and stable teams, balancing performance with stability [4]. - The recommendation is to wait for short-term market risks to fully materialize before increasing positions, while maintaining a focus on sectors with clear growth trends like AI and innovative pharmaceuticals [7].

Market Overview - The A-share market has shown a strong upward trend since August, with major indices reaching new highs and significant trading volume, indicating a bullish sentiment among investors [2][3] - As of September 4, over 94% of public funds have reported positive returns this year, with 397 funds achieving returns exceeding 50% [2][3] Fund Performance - Among the 13,110 public funds, 12,372 have positive returns, with 1,592 funds yielding over 30% and 397 funds exceeding 50% [2] - Active equity funds have performed particularly well, with an average return of 21.61%, and over 97% of these funds reporting positive returns [2][3] Top Performing Funds - The top-performing funds include Huatai-PineBridge Hong Kong Advantage Selection A and Yongying Technology Smart Selection A, both achieving returns over 160% [2][4] - Funds focusing on innovative pharmaceuticals and technology sectors have been particularly successful, with 12 active equity funds doubling their returns this year [4][5] Investment Trends - The strong performance of active equity funds is attributed to macroeconomic recovery and structural opportunities in the market, particularly in sectors like AI, new energy, and pharmaceuticals [3][4] - The investment logic for pharmaceutical funds emphasizes a "cyclical thinking" approach, anticipating a prolonged growth phase for innovative drugs due to upcoming commercialization and clinical data releases [5] Underperforming Funds - Despite the overall positive trend, 122 active equity funds have reported losses this year, with the worst-performing fund down 16.1% [6] - Many underperforming funds are heavily invested in manufacturing and technology sectors, which have struggled in the current market environment [6] Future Outlook - The outlook for active equity funds remains optimistic, with expectations of continued investment opportunities driven by policy support, liquidity improvements, and industry upgrades [7][8] - Investment strategies are shifting towards cyclical stocks, with a focus on sectors such as industrial metals, chemicals, and consumer goods [8]

Core Viewpoint - The public fund industry has shown signs of "mild recovery" in the first half of the year, with management fees reaching 62.09 billion yuan, a slight increase compared to the previous year, but still significantly lower than pre-reform levels [3][4][6]. Summary by Sections Management Fees - The total scale of the public fund industry reached 34.39 trillion yuan by the end of June, an increase of nearly 1.57 trillion yuan in the first half of the year, representing a year-to-date growth of 4.78% [5]. - The management fees collected by public funds in the first half of the year amounted to 62.09 billion yuan, a year-on-year increase of 10.18 billion yuan, or 1.67% [5][6]. - Despite the slight recovery, management fees are still down over 8.5 billion yuan compared to the 70.62 billion yuan reported before the fee reform in July 2023, indicating ongoing structural adjustments in the industry [6]. Fund Type Performance - Different types of funds have shown significant divergence in management fee income. Equity funds experienced the most notable decline, with management fees of 26.57 billion yuan, down 1.67 billion yuan year-on-year [6]. - Conversely, low-risk and specialty funds, such as money market and bond funds, saw management fee growth, with respective fees of 18.28 billion yuan and 14.62 billion yuan, both reaching historical highs [6][7]. Company Performance - Among the 193 fund management companies, 21 reported management fees exceeding 1 billion yuan, with the top ten companies maintaining a stable ranking [7]. - E Fund led with management fees of 3.918 billion yuan, although this was a decrease of 155 million yuan from the previous year [7][8]. - The competition among the lower-ranked companies is intense, with management fee differences of less than 1.2 billion yuan among them [8]. Profitability - A total of 66 fund companies reported a combined net profit of 17.673 billion yuan in the first half of the year, reflecting a year-on-year increase of over 10% [9][10]. - Approximately 88% of these companies were profitable, with 37 companies reporting net profit growth year-on-year [9]. - E Fund maintained its leading position with a net profit of 1.877 billion yuan, up 23.84% from the previous year [10]. Challenges for Smaller Firms - Some smaller firms, such as Jiutai and Jiangxin, reported losses, with revenues below 70 million yuan, highlighting their survival challenges [11]. - The operational difficulties faced by these smaller firms underscore their limitations in resources, branding, and research capabilities [11].

Core Viewpoint - The A-share market has shown significant strength in the first eight months of the year, leading to a strong performance of public equity funds, with many funds achieving over 100% returns [2][6][13]. Group 1: Market Performance - The main indices have experienced substantial gains, with the North Exchange 50 index rising by 51.49%, and several other indices, including the Sci-Tech Innovation 50 and the ChiNext index, increasing by over 30% [2][4]. - In August, the Shanghai Composite Index broke through the 3,800-point mark, reaching a 10-year high, with the Sci-Tech series indices showing strong performance, with increases of 32.25% and 28.00% respectively [4]. Group 2: Fund Performance - The average net value growth rate of active equity funds in the first eight months reached 23.83%, with the best-performing fund achieving a growth rate exceeding 175% [6][10][11]. - A total of 603 active equity funds have recorded a net value growth rate exceeding 50%, with 21 funds surpassing 100% [13][20]. - The average net value growth rates for ordinary stock funds and mixed equity funds were 28.38% and 28.79% respectively, indicating strong recovery in net values [9]. Group 3: Sector Opportunities - Structural opportunities have emerged in sectors such as the North Exchange, innovative pharmaceuticals, humanoid robots, AI, and semiconductors, contributing to the strong performance of funds managed by adept fund managers [12][20]. - The innovative pharmaceutical sector has been a standout performer, with the Hong Kong Stock Connect innovative pharmaceutical index showing a cumulative annual increase of 108.24% [24]. Group 4: Future Outlook - If the current market trends continue, 2025 is expected to be a breakout year for active equity fund performance [21]. - The market is experiencing a rebalancing of underlying funds, with indications of capital flowing from dollar assets to non-dollar assets, and from the bond market to the equity market [26].

Group 1 - The core viewpoint of the article highlights that funds focused on innovative pharmaceuticals have seen significant gains, with some funds increasing over 61% in the first half of the year [1] - The top-performing funds include several that are primarily invested in innovative drugs, with the highest return being 86.48% for the fund "汇添富音港优势精选A" [1] - Other notable funds in the top 16 also show strong performance, with returns ranging from 61.77% to 83.15% [1] Group 2 - The article suggests that innovative drugs can be pursued when the market declines, indicating a potential buying opportunity [2] - The "广发成长领航一年持有A" fund has a significant portion of its holdings in new consumer concepts, with major investments in companies like 泡泡玛特 and 老铺黄金 [3] - The fund manager 吴远怡 has demonstrated strong performance across various products, with most showing commendable returns [4] Group 3 - The historical performance of the "广发科技创新" fund shows a maximum drawdown of -53%, indicating high volatility [5] - Overall, the funds discussed are characterized by high volatility and significant drawdowns, making them more suitable for investors willing to buy during market dips [7] - The article emphasizes that these funds may not be suitable for low-risk investors due to their performance characteristics [7]